|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Prat A, Pineda E, Adamo B, Galván P,
Fernández A, Gaba L, Díez M, Viladot M, Arance A and Muñoz M:
Clinical implications of the intrinsic molecular subtypes of breast
cancer. Breast. 24(Suppl 2): S26–S35. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kocemba KA, Dulińska-Litewka J, Wojdyła KL
and Pękala PA: The role of 6-phosphofructo-2-kinase
(PFK-2)/fructose 2,6-bisphosphatase (FBPase-2) in metabolic
reprogramming of cancer cells. Postepy Hig Med Dosw. 70:938–950.
2016. View Article : Google Scholar
|
|
4
|
Yalcin A, Telang S, Clem B and Chesney J:
Regulation of glucose metabolism by
6-phosphofructo-2-kinase/fructose-2,6-bisphos-phatases in cancer.
Exp Mol Pathol. 86:174–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Okar DA, Manzano A, Navarro-Sabatè A,
Riera L, Bartrons R and Lange AJ: PFK-2/FBPase-2: Maker and breaker
of the essential biofactor fructose-2,6-bisphosphate. Trends
Biochem Sci. 26:30–35. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rider MH, Bertrand L, Vertommen D, Michels
PA, Rousseau GG and Hue L:
6-phosphofructo-2-kinase/fructose-2,6-bisphospha-tase: Head-to-head
with a bifunctional enzyme that controls glycolysis. Biochem J.
381:561–579. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim SG, Manes NP, El-Maghrabi MR and Lee
YH: Crystal structure of the hypoxia-inducible form of
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3): A
possible new target for cancer therapy. J Biol Chem. 281:2939–2944.
2006. View Article : Google Scholar
|
|
8
|
Clem BF, O'Neal J, Tapolsky G, Clem AL,
Imbert-Fernandez Y, Kerr DA II, Klarer AC, Redman R, Miller DM,
Trent JO, et al: Targeting 6-phosphofructo-2-kinase (PFKFB3) as a
therapeutic strategy against cancer. Mol Cancer Ther. 12:1461–1470.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Atsumi T, Chesney J, Metz C, Leng L,
Donnelly S, Makita Z, Mitchell R and Bucala R: High expression of
inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase
(iPFK-2; PFKFB3) in human cancers. Cancer Res. 62:5881–5887.
2002.PubMed/NCBI
|
|
10
|
O'Neal J, Clem A, Reynolds L, Dougherty S,
Imbert-Fernandez Y, Telang S, Chesney J and Clem BF: Inhibition of
6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and
the growth of HER2+ breast cancer. Breast Cancer Res
Treat. 160:29–40. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ge X, Lyu P, Cao Z, Li J, Guo G, Xia W and
Gu Y: Overexpression of miR-206 suppresses glycolysis,
proliferation and migration in breast cancer cells via PFKFB3
targeting. Biochem Biophys Res Commun. 463:1115–1121. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hu KY, Wang G, Liu PF, Cao YW, Wang YH,
Yang XC, Hu CX, Sun LJ and Niu HT: Targeting of MCT1 and PFKFB3
influences cell proliferation and apoptosis in bladder cancer by
altering the tumor microenvironment. Oncol Rep. 36:945–951. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu Y, An X, Guo X, Habtetsion TG, Wang Y,
Xu X, Kandala S, Li Q, Li H, Zhang C, et al: Endothelial PFKFB3
plays a critical role in angiogenesis. Arterioscler Thromb Vasc
Biol. 34:1231–1239. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Panigrahy D, Singer S, Shen LQ,
Butterfield CE, Freedman DA, Chen EJ, Moses MA, Kilroy S, Duensing
S, Fletcher C, et al: PPARgamma ligands inhibit primary tumor
growth and metastasis by inhibiting angiogenesis. J Clin Invest.
110:923–932. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim JW and Dang CV: Cancer's molecular
sweet tooth and the Warburg effect. Cancer Res. 66:8927–8930. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schoors S, De Bock K, Cantelmo AR,
Georgiadou M, Ghesquière B, Cauwenberghs S, Kuchnio A, Wong BW,
Quaegebeur A, Goveia J, et al: Partial and transient reduction of
glycolysis by PFKFB3 blockade reduces pathological angiogenesis.
Cell Metab. 19:37–48. 2014. View Article : Google Scholar
|
|
17
|
Ruiter GA, Zerp SF, Bartelink H, van
Blitterswijk WJ and Verheij M: Anti-cancer alkyl-lysophospholipids
inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway.
Anticancer Drugs. 14:167–173. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cardone MH, Roy N, Stennicke HR, Salvesen
GS, Franke TF, Stanbridge E, Frisch S and Reed JC: Regulation of
cell death protease caspase-9 by phosphorylation. Science.
282:1318–1321. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Qu J, Lu D, Guo H, Miao W, Wu G and Zhou
M: PFKFB3 modulates glycolytic metabolism and alleviates
endoplasmic reticulum stress in human osteoarthritis cartilage.
Clin Exp Pharmacol Physiol. 43:312–318. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chu IM, Hengst L and Slingerland JM: The
Cdk inhibitor p27 in human cancer: Prognostic potential and
relevance to anticancer therapy. Nat Rev Cancer. 8:253–267. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Slingerland J and Pagano M: Regulation of
the cdk inhibitor p27 and its deregulation in cancer. J Cell
Physiol. 183:10–17. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Calvo MN, Bartrons R, Castaño E, Perales
JC, Navarro-Sabaté A and Manzano A: PFKFB3 gene silencing decreases
glycolysis, induces cell-cycle delay and inhibits
anchorage-independent growth in HeLa cells. FEBS Lett.
580:3308–3314. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yalcin A, Clem BF, Imbert-Fernandez Y,
Ozcan SC, Peker S, O'Neal J, Klarer AC, Clem AL, Telang S and
Chesney J: 6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle
progression and suppresses apoptosis via Cdk1-mediated
phosphorylation of p27. Cell Death Dis. 5:e13372014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wagner KD, Cherfils-Vicini J, Hosen N,
Hohenstein P, Gilson E, Hastie ND, Michiels JF and Wagner N: The
Wilms' tumour suppressor Wt1 is a major regulator of tumour
angiogenesis and progression. Nat Commun. 5:58522014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Carmeliet P and Jain RK: Molecular
mechanisms and clinical applications of angiogenesis. Nature.
473:298–307. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Steidl C, Lee T, Shah SP, Farinha P, Han
G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, et al:
Tumor-associated macrophages and survival in classic Hodgkin's
lymphoma. N Engl J Med. 362:875–885. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yan F, Tan XY, Geng Y, Ju HX, Gao YF and
Zhu MC: Inhibition effect of siRNA-downregulated UHRF1 on breast
cancer growth. Cancer Biother Radiopharm. 26:183–189. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
29
|
Matsui TA, Murata H, Sowa Y, Sakabe T,
Koto K, Horie N, Tsuji Y, Sakai T and Kubo T: A novel MEK1/2
inhibitor induces G1/S cell cycle arrest in human fibrosarcoma
cells. Oncol Rep. 24:329–333. 2010.PubMed/NCBI
|
|
30
|
Bouïs D, Hospers GA, Meijer C, Molema G
and Mulder NH: Endothelium in vitro: A review of human vascular
endothelial cell lines for blood vessel-related research.
Angiogenesis. 4:91–102. 2001. View Article : Google Scholar
|
|
31
|
Lau WH, Pandey V, Kong X, Wang XN, Wu Z,
Zhu T and Lobie PE: Trefoil factor-3 (TFF3) stimulates de novo
angiogenesis in mammary carcinoma both directly and indirectly via
IL-8/CXCR2. PLoS One. 10:e01419472015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bagley RG, Walter-Yohrling J, Cao X, Weber
W, Simons B, Cook BP, Chartrand SD, Wang C, Madden SL and Teicher
BA: Endothelial precursor cells as a model of tumor endothelium:
Characterization and comparison with mature endothelial cells.
Cancer Res. 63:5866–5873. 2003.PubMed/NCBI
|
|
33
|
Minchenko OH, Tsuchihara K, Minchenko DO,
Bikfalvi A and Esumi H: Mechanisms of regulation of PFKFB
expression in pancreatic and gastric cancer cells. World J
Gastroenterol. 20:13705–13717. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chesney J:
6-phosphofructo-2-kinase/fructose-2,6-bisphospha-tase and tumor
cell glycolysis. Curr Opin Clin Nutr Metab Care. 9:535–539. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chesney J, Mitchell R, Benigni F, Bacher
M, Spiegel L, Al-Abed Y, Han JH, Metz C and Bucala R: An inducible
gene product for 6-phosphofructo-2-kinase with an AU-rich
instability element: Role in tumor cell glycolysis and the Warburg
effect. Proc Natl Acad Sci USA. 96:3047–3052. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Minchenko OH, Ogura T, Opentanova IL,
Minchenko DO, Ochiai A, Caro J, Komisarenko SV and Esumi H:
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene family
overexpression in human lung tumor. Ukr Biokhim Zh (1999).
77:46–50. 2005.
|
|
37
|
Minchenko OH, Ochiai A, Opentanova IL,
Ogura T, Minchenko DO, Caro J, Komisarenko SV and Esumi H:
Overexpression of
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4 in the human
breast and colon malignant tumors. Biochimie. 87:1005–1010. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yalcin A, Clem BF, Simmons A, Lane A,
Nelson K, Clem AL, Brock E, Siow D, Wattenberg B, Telang S, et al:
Nuclear targeting of 6-phosphofructo-2-kinase (PFKFB3) increases
proliferation via cyclin-dependent kinases. J Biol Chem.
284:24223–24232. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Doménech E, Maestre C, Esteban-Martínez L,
Partida D, Pascual R, Fernández-Miranda G, Seco E, Campos-Olivas R,
Pérez M, Megias D, et al: AMPK and PFKFB3 mediate glycolysis and
survival in response to mitophagy during mitotic arrest. Nat Cell
Biol. 17:1304–1316. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Clem B, Telang S, Clem A, Goswami U and
Chesney J: Inhibition of 6-phosphofructo-2-kinase suppresses breast
tumor growth in vivo. Cancer Res. 69(2 Suppl): 30642009. View Article : Google Scholar
|
|
41
|
Han J, Meng Q, Xi Q, Wang H and Wu G:
PFKFB3 was overexpressed in gastric cancer patients and promoted
the proliferation and migration of gastric cancer cells. Cancer
Biomark. 18:249–256. 2017. View Article : Google Scholar
|
|
42
|
Bobarykina AY, Minchenko DO, Opentanova
IL, Moenner M, Caro J, Esumi H and Minchenko OH: Hypoxic regulation
of PFKFB-3 and PFKFB-4 gene expression in gastric and pancreatic
cancer cell lines and expression of PFKFB genes in gastric cancers.
Acta Biochim Pol. 53:789–799. 2006.PubMed/NCBI
|
|
43
|
Ge X, Cao Z, Gu Y, Wang F, Li J, Han M,
Xia W, Yu Z and Lyu P: PFKFB3 potentially contributes to paclitaxel
resistance in breast cancer cells through TLR4 activation by
stimulating lactate production. Cell Mol Biol (Noisy-le-Grand,
France). 62:119–125. 2016.
|
|
44
|
Lu L, Chen Y and Zhu Y: The molecular
basis of targeting PFKFB3 as a therapeutic strategy against cancer.
Oncotarget. 8:62793–62802. 2017.PubMed/NCBI
|
|
45
|
Møller MB: P27 in cell cycle control and
cancer. Leuk Lymphoma. 39:19–27. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhao D, Besser AH, Wander SA, Sun J, Zhou
W, Wang B, Ince T, Durante MA, Guo W, Mills G, et al: Cytoplasmic
p27 promotes epithelial-mesenchymal transition and tumor metastasis
via STAT3-mediated Twist1 upregulation. Oncogene. 34:5447–5459.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Simon-Molas H, Nieves Calvo-Vidal M,
Castaño E, Bartrons R and Manzano A: Akt mediates TIGAR induction
in HeLa cells following PFKFB3 inhibition. FEBS Lett. 17:pp.
59020162016, https://doi.org/10.1002/1873-3468.12338.
|
|
48
|
Rodríguez-García A, Samsó P, Fontova P,
Simon-Molas H, Manzano A, Castaño E, Rosa JL, Martinez-Outshoorn U,
Ventura F, Navarro-Sabaté À, et al: TGF-β1 targets Smad, p38 MAPK,
and PI3K/Akt signaling pathways to induce PFKFB3 gene expression
and glycolysis in glioblastoma cells. FEBS J. 284:3437–3454. 2017.
View Article : Google Scholar
|
|
49
|
Guo C, Buranych A, Sarkar D, Fisher PB and
Wang XY: The role of tumor-associated macrophages in tumor
vascularization. Vasc Cell. 5:202013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang LZ, Zhang CQ, Yan ZY, Yang QC, Jiang
Y and Zeng BF: Tumor-initiating cells and tumor vascularization.
Pediatr Blood Cancer. 56:335–340. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cantelmo AR, Conradi LC, Brajic A, Goveia
J, Kalucka J, Pircher A, Chaturvedi P, Hol J, Thienpont B, Teuwen
LA, et al: Inhibition of the glycolytic activator PFKFB3 in
endothelium induces tumor vessel normalization, impairs metastasis,
and improves chemotherapy. Cancer Cell. 30:968–985. 2016.
View Article : Google Scholar : PubMed/NCBI
|
